Stock 002317 GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Guangdong Zhongsheng Pharmaceutical Co., Ltd.

Equities

002317

CNE100000HW4

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-07-15 pm EDT 		5-day change 1st Jan Change
11.05 CNY -1.16% Intraday chart for Guangdong Zhongsheng Pharmaceutical Co., Ltd. +0.18% -31.15%
Jul. 01 Zhongsheng Pharmaceutical's Unit Gets Nod to Market Gastric Protective Drug MT
May. 28 China Grants Approval to Zhongsheng Pharma's Eye Drops MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Zhongsheng Pharmaceutical's Unit Gets Nod to Market Gastric Protective Drug
MT
China Grants Approval to Zhongsheng Pharma's Eye Drops
MT
Guangdong Zhongsheng Pharmaceutical Co., Ltd. Approves Cash Dividend for 2023
CI
Guangdong Zhongsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Zhongsheng Pharma's Unit Gets Nod to Market Mirabegron
MT
Zhongsheng Pharma Chairman Plans Boosting Stake
MT
Guangdong Zhongsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Zhongsheng Pharmaceutical Gets Drug Registration Certificate for Carbocysteine Oral Solution
MT
Guangdong Zhongsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Zhongsheng Pharmaceutical Gets Nod to Register Moxifloxacin Hydrochloride Eye Drops
MT
Guangdong Zhongsheng Pharmaceutical Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 16 May 2023
CI
Guangdong Zhongsheng Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2022
CI
Guangdong Zhongsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Guangdong Zhongsheng Pharmaceutical Co., Ltd. Announces Final Dividend Profit Distribution Proposal for 2022
CI
Guangdong Zhongsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Zhongsheng Pharma Gets Conditional Market Approval For Oral COVID-19 Drug
MT
Zhongsheng Pharma Gets Regulatory Nod for Registration of Eye Drops
MT
Zhongsheng Pharma Exits Medical, Health Industry M&A Fund
MT
Guangdong Zhongsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
Zhongsheng Pharmaceutical’s Profit Plunges 30% in H1 Despite Revenue Growth
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 002317 Stock
  4. News Guangdong Zhongsheng Pharmaceutical Co., Ltd.
  5. Highlights